Alzinova AB

ALZ

SE0007413455

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:22:42 2024-04-26 am EDT			5-day change	1st Jan Change
1.156 ^SEK	-32.00%		-33.33%	-61.91%

Apr. 25	Sweden’s Alzinova Says CEO to Step Down by July-end	MT
Apr. 25	Kristina Torfgård Leaves the CEO Position At Alzinova Ab, Effective July 31, 2024	CI

Alzinova AB Elects Julian Aleksov as Board Member and Chairman of the Board of Directors

May 30, 2023 at 09:50 am EDT

Alzinova AB (publ) at its annual general meeting held on 30 May 2023 elected Julian Aleksov, as Board members. Julian Aleksov was elected as the chairman of the Board of Directors.

Latest news about Alzinova AB

Sweden’s Alzinova Says CEO to Step Down by July-end	Apr. 25	MT
Kristina Torfgård Leaves the CEO Position At Alzinova Ab, Effective July 31, 2024	Apr. 25	CI
Alzinova AB Completes In-Depth Analysis of Data from Part A of Alzinova's Phase 1B Study with the Vaccine Candidate ALZ-101	Apr. 11	CI
Alzinova AB Announces All Patients in the Extension Part of the Phase 1B Study Have Received Their Last Dose of ALZ-101	Apr. 04	CI
Sweden's Alzinova Names Interim CFO	Mar. 08	MT
Alzinova AB Announces CFO Changes	Mar. 08	CI
Alzinova AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 28	CI
Alzinova Secures Regulatory Approval to Test Higher Dose of Vaccine Candidate in Ongoing Trial	Feb. 13	MT
Alzinova AB Receives Regulatory Approval to Evaluate A Higher Dose of the Vaccine Candidate Alz-101 in the Ongoing Phase 1B Study	Feb. 13	CI
SynAct Pharma Names New Chief Medical Officer	Feb. 01	MT
Alzinova AB Announces Primary Analysis Confirms Positive Phase 1B Results with ALZ-101 against Alzheimer's	Jan. 30	CI
Alzinova AB Announces Retiremet of Håkan Skogström as CFO	Dec. 01	CI
Alzinova AB Announces Positive Phase 1b Results with the Vaccine Candidate ALZ-101 Against Alzheimer's Disease	Nov. 29	CI
Alzinova AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
EU Medicines Regulator OKs Alzinova's Clinical Development Program for Alzheimer's Drug Candidate	23-09-26	MT
Alzinova AB Receives Positive Response from the European Medicines Agency EMA	23-09-26	CI
Alzinova Enters Peptide Production Agreement with Manufacturer	23-08-25	MT
Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-17	CI
Alzinova Completes Pre-IND Meeting with US FDA on Alzheimer's Drug Candidate	23-08-09	MT
Alzinova AB Successfully Concludes A Pre-IND Meeting with the US Food and Drug Administration Receiving Positive Feedback on the Planned Clinical Development Program for the Vaccine Candidate ALZ-101	23-08-09	CI
Alzinova Appoints New Chief Medical Officer	23-08-03	MT
Alzinova AB Appoints Kirsten Harting as New Chief Medical Officer, Effective from August 14, 2023	23-08-03	CI
Alzinova AB Submits Request for Pre-IND Meeting with FDA and Applies for EMA Scientific Advice	23-06-13	CI
Alzinova AB Elects Julian Aleksov as Board Member and Chairman of the Board of Directors	23-05-30	CI
Alzinova AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-17	CI

Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâs disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ALZINOVA AB	-61.91%	4.7M
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research

Alzinova AB

Equities

ALZ

SE0007413455

Biotechnology & Medical Research

Alzinova AB Elects Julian Aleksov as Board Member and Chairman of the Board of Directors

Latest news about Alzinova AB

Chart Alzinova AB

Company Profile

Income Statement Evolution

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research